Glucocorticoids are potent immunosuppressive drugs, but their mechanism is poorly understood. Nuclear factor kappa B (NF-KB), a regulator of immune system and inflammation genes, may be a target for glucocorticoid-mediated immunosuppression. The activation of NF-KB involves the targeted degradation of its cytoplasmic inhibitor, IKBY, and the translocation of NF-KB to the nucleus. Here it is shown that the synthetic glucocorticoid dexamethasone induces the transcription of the IKBc gene, which results in an increased rate of IKBa protein synthesis. Stimulation by tumor necrosis factor causes the release of NF-KB from IKBa. However, in the presence of dexamethasone this newly released NF-KB quickly reassociates with newly synthesized IKBc, thus markedly reducing the amount of NF-KB that translocates to the nucleus. This decrease in nuclear NF-KB is predicted to markedly decrease cytokine secretion and thus effectively block the activation of the immune system. Glucocorticoids (GCs) have been used for decades as clinical tools to suppress both the immune response and the processes of inflammation (1), yet the immLunosuppressive mechanism by which these drugs act is poorly understood. GCs bind to a cytoplasmic glucocorticoid receptor (GR), a member of the steroid hormone receptor superfamily, which then translocates to the nucleus as a transcription factor (2). Transcriptional activation of cytokine and cell adhesion genes is critical in the activation of tlhe immune and inflammation systems and is repressed by GCs (3). GC repressive elements, however, have not been found in cytokine promoters. In addition, the GR is able to repress the transcription factor AP-1 through a cross-coupling mechanism (4), yet AP-1 regulates only a small number of GC-sensitive cytokine promoters. GCs can also repress members of the NF-KB-Rel transcription factor family (5, 6). NF-KBresponsive elements are required for the function of many cytokine promoters (7) :!To whom correspondence should be addressed.
and NF-KB-responsive elements in the interleukin-6 (IL-6) and IL-8 promoters have been implicated in GC-mediated suppression (5) . A major form of NF-KB is composed of a dimer of p50 and p65 (ReIA) subunits, and this complex is retained in the cytoplasm by repressor molecules that contain ankyrin repeat motifs (7) . These inhibitory molecules include the IKB family:
IKBox, P, and 'y, as well as the NF-KB precursor molecules plO5 (NF-KB1) and plOO (NF-KB2) (7) (8) (9) . Although a cross-coupling mechanism of inhibition exists between NF-KB and tlhe GR (5, 6) , it cannot fully explain the ability of GCs to inhibit NF-KB. Here it is shown that GCs induce the transcription of the gene encoding IKBox. The increase in IKBox mRNA results in increased IKBo-protein synthesis, which effectively inhibits NF-KB activation.
We initiated this study by extending our analysis of the ability of the synthetic GC dexamethasone (DEX) to block the induction of NF-KB-like DNA binding activities in several cell types and by several different inducers. As shown previously (6) , DEX blocks the induction of NF-KB by tumor necrosis factor ox (TNF-ox) in HeLa cells (Fig. IA, left panel) as well as induction by IL-1 (10) . The identity of this complex as NF-KB was determined by supershift experiments (10) . DEX inhibited the induction of NF-KB in the monocytic cell line THP-1, mediated by TNF-c- (Fig. IA, middle panel) and by lipopolysaccharide (LPS) (10) . DEX also inhibited the TNF-o-mediated induction of NF-KB in the murine T cell hybridoma 2B4 (Fig. IA, right panel) . In addition, thymocytes and lymph nodes derived from mice treated with monoclonal antibody (mAb) to CD3 in combination with DEX no longer express NF-KB activity as compared with mice treated with CD3 mAb alone (11) . This effect of DEX requires protein synthesis, as it is blocked by cycloheximide (CHX) (Fig. IA, right panel) .
DEX treatment results in a reduction in NF-KB-mediated gene expression as measured by transfected reporter constructs (5, 6, 11) . Previous work indicated that the inhibition of NF-KB was the result in part of a decrease in nuclear translocation after stimulation with TNF-ox.
We wanted to determine if the DEXmediated reduction of nuclear p65 translocation, after TNF-c-stimulation, correlated with an increase in IKBox. IKBox is rapidly degraded after TNF-a-addition (7, 12) 1 and 6) . The average increase in IKBox protein was measured as 1.5-fold (n = 10). DEX pretreatment h-ad no effect on cytoplasmic p65 amounts (10) . In addition, DEX pretreatment slowed the disappearance of IKBo-mediated by TNF-ox. After 1 hour of TNF-a-treatment, the amount of translocated nuclear p65 was reduced approximately 50% in DEX-treated cultures as compared with untreated cultures (Fig. iB, bottom panels; compare lanes 5 and 10) . THP-1 cultures induced with TNF or LPS gave similar results (10) . We then considered whether DEX might induce other NF-KB-sequestering molecules such as the recently cloned IKBI (13) . HeLa cells cultured with DEX for 5 hours were compared with untreated HeLa cultures, and no differences were found in amounts of IKBI (10) . Whereas IKBI is insensitive to TNF treatment, LPS induction for 2 hours is sufficient to induce release of NF-KB and IKBI degradation (13) .
Pretreatment with DEX had no effect on either IKB3 amounts or LPS-induced IKBI loss (10) . Thus, DEX selectively increases the abundance and overall stability of the IKBa population.
In order to determine if the GC-mediated increase in lKBa protein was preceded by an increase in IKBa mRNA, Northern (RNA) blot analysis was done on mRNA derived from HeLa cultures treated with DEX for increasing periods of time. DEX induced a marked increase in lKBa mRNA abundance, which peaked by 1 to 2 hours ( Fig. 2A) and in some cases remained elevated for over 20 hours (10) . A similar pattern was observed with THP-1 cultures (10) and is consistent with other studies (11) . We tested whether protein synthesis was necessary for this induction of the IKBa message. HeLa cultures were treated with DEX in the absence or presence of CHX, and IKBa mRNA amounts were compared by Northern blot analysis. CHX alone induced IKBa mRNA, as has been observed for other messages ( intermediary factor which must then induce the IKBa message. These data suggest that GCs directly activate IKBa gene transcription. We tested this hypothesis by performing run-on transcription assays on HeLa and THP-1 cultures after DEX treatment for various periods of time ( RNA was prepared as described (17) . Equal amounts of RNA (10 ,g ) as determined by ethidium-stained 28S RNA were size separated by formaldehyde acrylamide gel electrophoresis, blofted to Zetaprobe (Bio-Rad), and processed according to the manufacturer's instructions. The blot was probed first with a MAD-3-IKBa complementary DNA (cDNA) (8) labeled by random priming. Subsequently, the blot was reprobed with a cyclophilin (Cyc.) cDNA (labeled as above) as a control RNA. Prehybridization and washing were done according to Bio-Rad's recommendations.
(B) Cultures were treated with CHX (10 ng/ml) for 1 hour; 1 0-M DEX was then added to appropriate cultures for an additional 2.5 hours, and RNA was harvested and analyzed by Northern blot as described above. (C) Run-on transcription assays were done on cultures treated with either 10-7 M DEX or TNF-a (1 ng/ml) for varying periods of time as shown. Nuclei were isolated, and run-on transcriptions were done as described (18) . The filters were exposed to a Phospholmager (Molecular Dynamics) screen, and the bands were quantitated. IKBax and IL-8 transcription were normalized to actin transcription. The data are representative of four independent experiments.
for at least 2 hours. In order to quantitate the effect, we normalized the IKBa signal to an actin control, thereby measuring the increase in transcription as almost 10-fold (Table 1) . We cannot discount the possibility that actin transcription may be slightly inhibited by DEX treatment, thus decreasing the amount of the induction, but the interpretation of the data remains unaffected. In addition, DEX had no effect on transcription of genes encoding c-Myc or TNF-a (10). TNF-a treatment, in comparison, induces both IKBa and IL-8 transcription ( Fig. 2C and Table 1 ). No change in IKBa mRNA stability was detected as measured after actinomycin D treatment in the absence or presence of DEX (10) . Preliminary data indicated that a IKBa promoter construct extending to position -600 was not activated by DEX (10), which suggests that the putative GC-responsive element is located further upstream or within the gene. Taken together, these data suggest that DEX increases IKBa protein abundance through an increase in gene transcription. The increase in IKBa gene transcription induced by DEX was much greater than the average increase in IKBa protein abundance as measured by protein immunoblot. We thus wanted to determine if the rate of IKBa protein synthesis increased in a manner similar to that of the mRNA population. We metabolically labeled HeLa cells in the absence or presence of DEX, prepared whole-cell extracts, and immunoprecipitated with an antibody specific for either IKBa or p65. DEX induced a three-to fivefold increase in the rate of incorporation of 35S-labeled methionine into the IKBa pool (Fig. 3A, compare lanes 1 and 3) . The p65 antiserum immunoprecipitated almost as much labeled IKBa as did the IKBa antiserum, suggesting that the majority of newly synthesized IKBo was associated with p65 (Fig. 3A, compare lanes 3 and 4) . Detection of coimmunoprecipitated p65 by the IKBo antiserum was obscured by a comigrating nonspecific band (Fig. 3A,  lanes 1 to 3) . In addition, the degree of incorporation of label into the p65 pool was Fig. 20 titated with a Phospholmager. Radioactivity w ized to actin and expressed as fold increase ove much reduced as compared with lKBot, even though the two proteins contained similar numbers of methionines, indicating that the rate of p65 synthesis was low. These data indicate that newly synthesized lKBo is incorporated into preexisting NF-KB complexes, which is consistent with previous results (14). We tested this hypothesis further by labeling HeLa cultures for short periods of time and determining the efficiency of immunoprecipitation of IKB by the two antisera. After a 15-min pulse, extract was prepared and divided into identical aliquots, one of which was incubated with the IKBo antisera and the other with the p65 antisera. Once again, the IKBo signal derived from the p65 immunoprecipitation was similar to that derived from the IKBot immunoprecipitation ( and 2). Analysis of the supernatants indicated that the antibodies accounted for all of the signal (Fig. 3B , Sup. 1 and Sup. 2). Thus, all of the surviving newly synthesized IKBo protein was rapidly associated with NF-KB. This is consistent with the observation that free IKBo is intrinsically unstable and rapidly degraded (14). In the absence of DEX, TNF-ot treatment results in the transient loss of IKBo, which allows NF-KB to translocate to the nucleus (12) . We wanted to observe the effect of TNF-ot treatment on the DEXinduced pool of newly synthesized IKBot associated with NF-KB. To this end, HeLa cultures were metabolically labeled in the absence or presence of DEX. TNF-ot was then added and extracts were prepared at various times. The extracts were immunoprecipitated with the p65-specific antibody, and the resultant material was analyzed by SDS-polyacrylamide gel electrophoresis (PAGE). As expected, TNF-ot treatment in TNF-cx (1 ng/ml) was then added in the presence of carrier bovine serum albumin. Extracts were prepared by lysis in RIP buffer as described (19) and incubated with 1 ,ul of antiserum to p65 in the absence or presence of 1 ,ul of competing peptide as shown at the top of the panel. PAS pellets were extensively washed, and immunoprecipitated proteins were analyzed by SDS-PAGE. (B) HeLa cultures were metabolically labeled in the presence or absence of 10-7 M DEX as described above. Plates were washed with PBS and either harvested or treated with chase medium containing TNF-cx (1 ng/ml). After 30 min, plates were harvested and extracts were incubated with antiserum to p65 and processed as described above.
the absence of DEX resulted in the rapid loss of p65-associated IKBo (Fig. 4A) . In the presence of DEX, the amount of newly synthesized IKBo associated with p65 was greatly increased (Fig. 4A ; compare lanes 2 and 6). When treated with TNF-ot and DEX, the amount of newly synthesized IKBot associated with p65 remained elevated (Fig. 4A) . Thus, DEX treatment stabilizes the overall association of p65 with the pool of newly synthesized IKBot even in the presence of an inducer like TNF-ot.
This result could be explained either by the inhibition by DEX of the TNF-ot-mediated release of NF-KB from IKBo (for example, by affecting IKBo phosphorylation) or by the induction of the reassociation of newly synthesized IKBot with newly released NF-KB. These possibilities can be distinguished by performing a pulse-chase experiment and treating HeLa cultures with TNF-ot during the chase. Under chase conditions, newly synthesized IKBo protein has a much lower specific activity. Thus, if DEX blocks the TNF-ot-mediated release of NF-KB, the IKBo signal should remain relatively unchanged. If, in the presence of TNF-o, newly synthesized IKBo (low specific activity) replaces preexisting lKBo (high specific activity), then the IKBo signal should sub- abolically labeled in the absence or presence of DEX for several hours. The labeling medium was then replaced with chase medium containing DEX and TNF-ox. Cultures were harvested and extracts were immunoprecipitated with the p65-specific antibody. Under these conditions, the IKBox signal rapidly disappeared (Fig. 4B) . Thus, DEX does not appear to alter the signal transduction pathway leading to the induced dissociation of NF-KB and IKB x.
Together, these data indicate that DEX treatmnent induces the transcription of the IKBo-gene. This induction results in the increased synthesis of IKBo-protein. This increase in protein synthesis leads to the rapid turnover of IKB(x protein associated with preexisting NF-KB complexes. In the presence of an activator suclh as TNF-u_4, newly released NF-KB reassociates with the DEX-induced IKBox and thus reduces the amount of NF-KB translocating to the nucleus. Additionally, newly synthesized IKB x may enter the nucleus and inhibit NF-KB DNA binding (15) . A model of this process is shown in Fig. 5 . Consistent with this model, we show that the GC-mediated inhibition of NF-KB induction by means of TNF-ox is blocked by CHX (Fig. 1) . Previously we and others showed that activated GR could physically associate with NF-KB subunits and that DEX represses the DNA binding activity of nuclear NF-KB (5, 6 ).
Here we demonstrate a second independent mechanism through which the NF-KB and GC signal transduction systems interact. As NF-KB is a critical regulator of cytokine genes, the inhibition of the activity of this transcription factor would effectively block cytokine secretion, thus explaining an immunosuppressive function of GCs. It has also been reported recently that salicylates, at concentrations corresponding to doses prescribed for arthritis patients, also block NF-KB activity (16) . Thus, NF-KB activation serves as a target for two distinct immunosuppressive therapies. The presence of multiple levels of interaction between the NF-KB and GC systems suggests that these interactions may have evolved to serve a physiological role in the development of the immune system and in modulation of the immune response.
Glucocorticoids are among the most potent anti-inflammatory and immunosuppressive agents. They inhibit synthesis of almost all known cytokines and of several cell surface molecules required for immune function, but the mechanism underlying this activity has been unclear. Here it is shown that glucocorticoids are potent inhibitors of nuclear factor kappa B (NF-KB) activation in mice and cultured cells. This inhibition is mediated by induction of the IKBOL inhibitory protein, which traps activated NF-KB in inactive cytoplasmic complexes. Because NF-KB activates many immunoregulatory genes in response to pro-inflammatory stimuli, the inhibition of its activity can be a major component of the anti-inflammatory activity of glucocorticoids.
Glucocorticoids ( anti-inflammatory agents (1) . Interference with GC action or synthesis increases animal mortality after challenge with bacterial superantigens (2) . GCs induce lymphocyte apoptosis (1, 3) and inhibit synthesis of lymphokines (4) and cell surface molecules required for immune functions (5) . In spite of the widespread use of GCs, the molecular mechanisms that underlie their therapeutic effects are poorly understood (1) . GCs induce target genes through the glucocorticoid receptor (GR), a ligand-activated tran-
